In addition, recent results from a clinical phase 2a study (Safety and Tolerability Study of AZD4831 in Patients With Heart Failure, SATELLITE) revealed therapy with the MPO inhibitor AZD4831 to be well tolerated and safe in heart failure patients with preserved ejection fraction.45 This evidence concerns the gene MPO and heart failure.